Best Peptides for Fat Loss: Complete Evidence Ranking 2026

Multiple peptides claim fat loss benefits. Evidence quality varies dramatically. This guide ranks peptides by evidence strength, realistic efficacy, and safety.

Semaglutide (Wegovy, Ozempic)

Evidence tier: Strong (FDA-approved)

Mechanism: GLP-1 receptor agonist; reduces appetite, increases satiety, slows gastric emptying, improves glucose control.

Weight loss efficacy: 15-22% of body weight over 68 weeks in clinical trials (STEP 1-4). Average weight loss ~15 kg for 80 kg patient.

Human trials: 4,500+ patients in large, rigorous RCTs. FDA approval based on efficacy and safety data.

Safety profile: Well-characterized; common side effects (nausea, vomiting, diarrhea) are dose-dependent and often transient.

Cost: $300-1,500/month depending on formulation and source.

Timeline: Weeks for appetite suppression; 8-12 weeks for significant weight loss.

Recommendation: Gold standard for weight loss peptides. Proven, FDA-approved, most evidence.

---

Tirzepatide (Zepbound, Mounjaro)

Evidence tier: Strong (FDA-approved)

Mechanism: Dual GLP-1/GIP receptor agonist; superior appetite suppression and metabolic rate elevation vs. semaglutide.

Weight loss efficacy: 18-22% of body weight over 72 weeks. Superior to semaglutide in head-to-head comparisons.

Human trials: 2,500+ patients; FDA approval in 2023.

Safety profile: Similar to semaglutide; slightly higher GI side effect rates in some trials.

Cost: $400-2,000/month.

Timeline: Similar to semaglutide; weeks for effect onset.

Recommendation: Slightly superior to semaglutide (better weight loss); first-line if available.

Retatrutide (Triple GLP-1/GIP/GCG agonist)

Evidence tier: Moderate (late-stage development)

Mechanism: Triple receptor agonist combining appetite suppression + metabolic rate elevation.

Weight loss efficacy: 24% of body weight over 48 weeks in Phase 2b REMODEL trial. Superior to semaglutide/tirzepatide.

Status: Not yet FDA-approved (as of early 2026); expected approval within 2026.

Human trials: 500+ patients; promising Phase 2b data.

Safety profile: Under evaluation; expected similar GI side effects to GLP-1s but potentially higher due to triple mechanism.

Cost (projected): $400-2,000/month (estimate).

Timeline: Expected availability 2026.

Recommendation: Most promising emerging option. Wait for approval and longer-term safety data; superior weight loss vs. current options.

MOTS-c (Mitochondrial Peptide)

Evidence tier: Weak

Weight loss efficacy: Zero human weight loss studies published. Only animal evidence for metabolic improvement.

Status: Research compound; not approved anywhere.

Recommendation: Not suitable for weight loss. Only animal evidence; no human data.

---

AOD-9604 (HGH Fragment)

Evidence tier: Very Weak

Mechanism: Direct lipolysis stimulation via β-adrenergic receptors.

Weight loss efficacy: ~5 kg over 12 weeks in one small pilot study (80 patients, non-rigorous). No large RCTs.

Human trials: One pilot; no follow-up studies.

Status: Research compound; no regulatory approval.

Cost: $100-250/month.

Recommendation: Not recommended for weight loss. Minimal evidence (5 kg speculative); inferior to semaglutide's proven 15-22 kg. Better alternatives available.

| Peptide | Evidence Tier | Weight Loss | Trials | FDA Status | Cost | |---------|---------------|-------------|--------|-----------|------| | Retatrutide | Moderate | 24% (500 patients) | Phase 2b | Pending 2026 | $400-2,000 | | Tirzepatide | Strong | 18-22% (2,500 patients) | Approved | FDA-approved | $400-2,000 | | Semaglutide | Strong | 15-22% (4,500 patients) | Approved | FDA-approved | $300-1,500 | | MOTS-c | Weak | Unknown (0 human trials) | Animal only | No | $150-300 | | AOD-9604 | Very Weak | ~5% (1 pilot, 80 patients) | 1 pilot | No | $100-250 |

Key takeaway: Evidence gap is enormous. Semaglutide = 22 kg proven. AOD-9604 = 5 kg speculative.

If you want proven, FDA-approved, accessible: - Start with semaglutide (most accessible, most evidence, good efficacy) - Upgrade to tirzepatide if semaglutide insufficient (better efficacy, similar cost)

If you want cutting-edge, expect superior results, willing to wait for approval: - Wait for retatrutide (expected 2026 approval; superior efficacy)

If you want to optimize weight loss: - Combine with lifestyle: GLP-1s work best with whole-foods diet, exercise, sleep, stress management - Timeline: Expect 15-22 kg loss over 12 months with semaglutide; similar or better with tirzepatide/retatrutide - Consider: GLP-1s are adjunctive to lifestyle change, not replacements

DO NOT use: - AOD-9604 (minimal evidence, inferior to proven options) - MOTS-c (zero human weight loss data) - Any unproven metabolism peptide when proven options exist

Semaglutide outcomes: - Average: 15-22 kg (33-49 lbs) over 68 weeks - Range: 5-30 kg depending on baseline, adherence, lifestyle - Responders (~70%): 15-25 kg loss - Non-responders (~30%): <5 kg loss

Tirzepatide outcomes: - Average: 18-22 kg over 72 weeks (better than semaglutide) - Range: 8-35 kg - Responders: 20-30 kg loss

Critical factors for success: - Diet quality (GLP-1 suppresses appetite; you must eat nutritious food) - Adherence (consistent peptide dosing + lifestyle) - Sleep (poor sleep impairs weight loss even with GLP-1) - Stress management (cortisol opposes weight loss) - Exercise (improves outcomes, especially for muscle preservation)

Typical timeline: - Weeks 1-2: Appetite suppression, nausea possible - Weeks 2-4: Initial weight loss (water, often 2-5 lbs) - Weeks 4-12: Accelerating weight loss (2-3 lbs/week if diet good) - Weeks 12+: Continued loss; rate slows over time

Important: Weight loss plateaus are normal; often resolve with dose increase or dietary adjustment. This is not failure.

Tier 1: Semaglutide or Tirzepatide — proven, FDA-approved, 15-22% weight loss, most accessible.

Tier 2 (wait for 2026): Retatrutide — emerging, superior 24% weight loss, but approval pending.

DO NOT use: AOD-9604 or MOTS-c — minimal evidence; inferior to proven options.

Most effective strategy: Tirzepatide (if available) OR Semaglutide + whole-foods diet + exercise + sleep management + stress reduction.

Realistic expectation: 15-25 kg weight loss over 12 months (semaglutide); 18-30 kg (tirzepatide); 24%+ (retatrutide when approved).

Key insight: GLP-1s work because they address appetite (neurological problem). Lifestyle changes are still essential; the peptide makes adherence possible.

Most important: Combine with foundational health (diet, exercise, sleep, stress). Peptides amplify good habits but cannot overcome poor habits.